PRRT as Neoadjuvant Treatment in NET

  • Anna Sowa-Staszczak
  • Alicja Hubalewska-Dydejczyk
  • Monika Tomaszuk
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 194)

Abstract

This chapter describes the possibility of using peptide receptor radionuclide therapy (PRRT) as neoadjuvant treatment. PRRT is acknowledged to be a palliative treatment. Recently it has been reported that tumor size decrease followed by surgical intervention might be achieved in patients with neuroendocrine tumors (NETs) treated with somatostatin analogs labeled with beta emitters. Such outcome of therapy has been described in a relatively small group of patients. In those patients, the treatment enabled total or partial excision of the tumor, also with liver metastases. Reduction of tumor dimensions or total excision of the tumor corresponded with prolongation of overall survival. The discussed papers on this subject differ in details of treatment (utilization of various isotopes, total activity of the isotope, or combination with radiosensitizing chemotherapy). The chapter presents a brief review of recently published manuscripts.

Keywords

Liver Metastasis Peptide Receptor Radionuclide Therapy Pancreatic Tail Pancreatic Neuroendocrine Tumor Decrease Tumor Size 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

CT

Computed tomography

Ki index

Proliferation index

NET

Neuroendocrine tumor

PET/CT

Positron emission tomography/computed tomography

PNT

Pancreatic neuroendocrine tumor

PRRT

Peptide receptor radionuclide therapy

RECIST

Response evaluation criteria for solid tumors

SPECT-CT

Single-photon emission computed tomography

T1/2

Physical half-life

5FU

5-Fluorouracil

References

  1. Barber TW, Hofman MS, Thomson BN et al (2012) The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumors resectable. Eur J Surg Oncol 38:64–71PubMedCrossRefGoogle Scholar
  2. Cremonesi M, Ferrari M, Bodei L et al (2006) Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 47:467–1475Google Scholar
  3. Faiss S, Pape UF, Bohming M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the international lanreotide and interferon alfa study group. J Clin Oncol 21:2689–2696PubMedCrossRefGoogle Scholar
  4. Kaemmerer D, Prasad V, Daffner W et al (2009) Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 15:5867–5870PubMedCrossRefGoogle Scholar
  5. Kazanjian KK, Reber HA, Hines OJ (2006) Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 141:765–769PubMedCrossRefGoogle Scholar
  6. Nomura N, Fujii T, Kanazumi N et al (2009) Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surgery 16:639–647CrossRefGoogle Scholar
  7. Oberg K, Kvols L, Caplin M et al (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966–973PubMedCrossRefGoogle Scholar
  8. Rinke A, Muller HH, Schade- Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumor: a report from the PROMID study group. J Clin Oncol 27:4656–4663PubMedCrossRefGoogle Scholar
  9. Sowa-Staszczak A, Pach D, Chrzan R et al (2011) Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumors (NETs). Eur J Nucl Med Mol Imaging 38:1669–1674PubMedCrossRefGoogle Scholar
  10. Stoeltzing O, Loss M, Huber M et al (2010) Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg 395:185–192PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Anna Sowa-Staszczak
    • 1
  • Alicja Hubalewska-Dydejczyk
    • 1
  • Monika Tomaszuk
    • 1
  1. 1.Department of EndocrinologyJagiellonian University Medical CollegeKrakowPoland

Personalised recommendations